Brimonidine Tartrate

酒石酸溴莫尼定

Report date: 2026/04/24 20:01:59
NME

Base Information

Drug NameBrimonidine Tartrate
Drug Alias NameBrimonidina溴莫尼定BrimonidineAiphagan Ophthalmic Solution 0.1%Brimonidinum +[20] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAdrenergic receptors alpha-2 agonists
TargetsAdrenergic receptors alpha-2
Therapy Area/IndicationsVisual AcuityAlcohol-Related DisordersFlushing +[18] 
Global Approved IndicationsRosaceaGlaucoma, Open-AngleOcular Hypertension
Approved Indications in ChinaGlaucoma, Open-AngleOcular Hypertension
Original Approved Country/TerritoryUnited States
Original Approved Date1996/09/06
Country/TerritoryCanadaUnited StatesSweden +[16] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesAllergan Plc
China Registration ClassN/A

Develop Information

Active CompaniesShenzhen Pharmayi Pharmaceutical Technology Co LtdTarian PharmaChina Medical System Holdings Ltd +[9] 
Inactive CompaniesHeinrich Heine University DusseldorfUniversity Of California San FranciscoSun Pharma Advanced Research Company Ltd +[11] 
Active IndicationsRosaceaGlaucoma, Open-AngleOcular Hypertension +[4] 
Inactive IndicationsVisual AcuityAlcohol-Related DisordersFlushing +[14] 

Other Information

ATC CodeD11AX21S01EA05
Related LinksWikipediaDrugBankKEGG